echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet: Repeated intravenous cardiomyocyte-derived cell therapy in advanced Duchenne muscular dystrophy (HOPE-2): a multicenter, randomized, double-blind, placebo-controlled phase 2 trial

    Lancet: Repeated intravenous cardiomyocyte-derived cell therapy in advanced Duchenne muscular dystrophy (HOPE-2): a multicenter, randomized, double-blind, placebo-controlled phase 2 trial

    • Last Update: 2022-04-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Duchenne muscular dystrophy is a severe, progressive, X-linked disease that affects both skeletal and cardiac muscle and severely reduces life expectancy
    .


    Patients with Duchenne muscular dystrophy develop progressive quadriplegia, restrictive lung disease, and worsening cardiomyopathy; these factors combine to eventually lead to death, usually in the second to fourth decade


     Duchenne muscular dystrophy is a severe, progressive, X-linked disease that affects both skeletal and cardiac muscle and severely reduces life expectancy


    Immune cardiosphere-derived cells (CDCs) are a type of stromal or precursor cells that have been shown in preclinical and clinical studies to exert immunomodulatory, anti-fibrotic and regenerative roles in malnutrition and heart failure (Appendix 4-12 )


    In an experimental model of Duchenne muscular dystrophy, cardiomyocyte-derived cells (CDCs) ameliorated skeletal and cardiac muscle deterioration
    .


    A study published today in The Lancet evaluated the long-term safety and efficacy of repeated intravenous administration of CAP-1002 in Duchenne muscular dystrophy in the HOPE-2 trial


    A study published today in The Lancet evaluated the long-term safety and efficacy of repeated intravenous administration of CAP-1002 in Duchenne muscular dystrophy in the HOPE-2 trial


    In this multicenter, randomized, double-blind, placebo-controlled, phase 2 multicenter trial , patients 10 years of age or older with Duchenne muscular dystrophy were enrolled at seven centers in the United States
    .


    Patients were randomly assigned (1:1) to receive IV infusions of CAP1002 (1.


    Multicenter, randomized, double-blind, placebo-controlled phase 2 multicenter trial

    • Between March 1, 2018 and March 31, 2020, 26 male patients with Duchenne muscular dystrophy were enrolled, 8 of whom were randomly assigned to the CAP-1002 group and 12 to the placebo group (6 was not randomly assigned due to screening
      failure) .
    • Among patients who received post-treatment PUL1.
      2 assessments (8 in the CAP-1002 group and 11 in the placebo group), the mean 12-month change in median elbow PUL1.
      2 favored CAP-1002 over placebo (100 Quantile difference 36.
      2, 95% confidence interval 12.
      7-59.
      7; difference 2.
      6 points; p=0.
      014)
      .
    • Infusion-related anaphylaxis was observed in 3 patients with no long-term sequelae, and 1 patient discontinued treatment due to severe anaphylaxis
      .


      No other major adverse reactions were noted, and no deaths occurred


      CAP-1002 cell therapy appears to be safe and effective in reducing the deterioration of upper extremity function in patients with advanced Duchenne muscular dystrophy


      McDonald CM, Marbán E, Hendrix S, et al.


      leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.